Von Willebrand disease and other bleeding disorders in obstetrics

doi:10.1017/CBO9780511526978.004

3 - Von Willebrand disease and other bleeding disorders in obstetrics

Published online by Cambridge University Press: 01 February 2010

Franklin Fuda D.O. and

Edited by

William F. Baker and

Franklin Fuda D.O.: Affiliation:
Fellow: Hematopathology Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Ravindra Sarode M.D.: Affiliation:
Professor of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Rodger L. Bick: Affiliation:
University of Texas Southwestern Medical Center, Dallas
Eugene P. Frenkel: Affiliation:
University of Texas Southwestern Medical Center, Dallas
William F. Baker: Affiliation:
University of California, Los Angeles
Ravi Sarode: Affiliation:
University of Texas Southwestern Medical Center, Dallas

Book contents

Get access

Summary

Introduction

Bleeding disorders in the female population often present unique challenges to an obstetrician. The hormonal and physical changes that occur during the menstrual cycle, pregnancy, childbirth, and the post-partum period continually place strain upon the hemostatic system. Although severe bleeding disorders are usually easily recognized, mild bleeding disorders often go undiagnosed due to the “mild degree” of signs and symptoms (e.g. slightly abnormal menstruation). Unfortunately, even these mild bleeding disorders often lead to a decrease in the quality of life, variable degrees of morbidity, and even life-threatening hemorrhage. Therefore, it is essential that the obstetrician be aware of the clinical clues, appropriate diagnostic tests, and treatment regimens for such disorders. This is particularly important for pregnant women, whose hemostatic system undergoes marked alterations in preparation for the unique challenge of delivery.

The hemostatic system

Basic knowledge of the hemostatic system assists in making clinical decisions regarding bleeding conditions in the obstetric population. Normal hemostasis is a highly regulated, physiologic process of clot formation and clot management that occurs in response to vascular injury. It involves 2 major systems: (i) primary hemostasis and (ii) secondary hemostasis. Although both systems are initiated at the same time and work together intricately to form stable platelet-fibrin clots, the influence that each system has upon clot formation in the arterial versus the venous systems is different.

Information

Type: Chapter
Information: Hematological Complications in Obstetrics, Pregnancy, and Gynecology , pp. 75 - 102

DOI: https://doi.org/10.1017/CBO9780511526978.004 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Kadir, R. A., Sabin, C. A., Pollard, D., et al. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia, 1998; 4(6): 836–41.CrossRef Google Scholar PubMed

Kouides, P. A., Phatak, P. D., Burkart, P., et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia, 2000; 6(6): 643–8.CrossRef Google Scholar PubMed

Rozeik, C. H.Gynecological disorders and psychological problems in 184 women with von Willebrand disease (vWD). Haemophilia, 1998; 4(3): 293.Google Scholar

Kulkarni, S., Dopheide, S. M., Yap, C. L., et al. A revised model of platelet aggregation. J. Clin. Invest., 2000; 105(6): 783–91.CrossRef Google Scholar PubMed

Shattil, S. J., Kashiwagi, H. and Pampori, N.Integrin signaling: the platelet paradigm. Blood, 1998; 91(8): 2645–57.Google Scholar PubMed

Watson, S. P. and Gibbins, J.Collagen receptor signalling in platelets: extending the role of the ITAM. Immunol. Today, 1998; 19(6): 260–4.CrossRef Google Scholar PubMed

Wickstrom, K., Edelstam, G., Lowbeer, C. H., et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand. J. Clin. Lab. Invest., 2004; 64(1): 31–40.CrossRef Google Scholar PubMed

Kadir, R. A., Lee, C. A., Sabin, C. A., et al. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br. J. Obstet. Gynaecol., 1998; 105(3): 314–21.CrossRef Google Scholar PubMed

Conti, M., Mari, D., Conti, E., et al. Pregnancy in women with different types of von Willebrand disease. Obstet. Gynecol., 1986; 68(2): 282–5.Google Scholar PubMed

Stirling, Y., Woolf, L., North, W. R., et al. Haemostasis in normal pregnancy. Thromb. Haemost., 1984; 52(2): 176–82.Google Scholar PubMed

Economides, D. L., Kadir, R. A. and Lee, C. A.Inherited bleeding disorders in obstetrics and gynaecology. Br. J. Obstet. Gynaecol., 1999; 106(1): 5–13.CrossRef Google Scholar PubMed

Cerneca, F., Ricci, G., Simeone, R., et al. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur. J. Obstet. Gynecol. Reprod. Biol., 1997; 73(1): 31–6.CrossRef Google Scholar PubMed

Dobrkovska, A., Krzensk, U. and Chediak, J. R.Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia, 1998; 4(Suppl 3): 33–9.CrossRef Google Scholar PubMed

Condie, R. G.A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy and in pregnancy complicated by pre-eclampsia. Br. J. Obstet. Gynaecol., 1976; 83(8): 636–9.CrossRef Google Scholar

Phillips, L. L., Rosano, L. and Skrodelis, V.Changes in factor XI (plasma thromboplastin antecedent) levels during pregnancy. Am. J. Obstet. Gynecol., 1973; 116(8): 1114–6.CrossRef Google Scholar PubMed

Beller, F. K. and Ebert, C.The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur. J. Obstet. Gynecol. Reprod. Biol., 1982; 13(3): 177–97.CrossRef Google Scholar PubMed

Hilgartner, M. W. and Smith, C. H.Plasma thromboplastin antecedent (Factor Xi) in the neonate. J. Pediatr., 1965; 66: 747–52.CrossRef Google Scholar PubMed

Fernandez, J. A., Estelles, A., Gilabert, J., et al. Functional and immunologic protein S in normal pregnant women and in full-term newborns. Thromb. Haemost., 1989; 61(3): 474–8.Google Scholar PubMed

Clark, P., Brennand, J., Conkie, J. A., et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb. Haemost., 1998; 79(6): 1166–70.Google Scholar PubMed

Edelstam, G., Lowbeer, C., Kral, G., et al. New reference values for routine blood samples and human neutrophilic lipocalin during third-trimester pregnancy. Scand. J. Clin. Lab. Invest., 2001; 61(8): 583–92.CrossRef Google Scholar PubMed

Kjellberg, U., Andersson, N. E., Rosen, S., et al. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb. Haemost., 1999; 81(4): 527–31.Google Scholar PubMed

Chabloz, P., Reber, G., Boehlen, F., et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br. J. Haematol., 2001; 115(1): 150–2.CrossRef Google Scholar PubMed

Cadroy, Y., Grandjean, H., Pichon, J., et al. Evaluation of six markers of haemostatic systems in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br. J. Obstet. Gynaecol., 1993; 100(5): 416–20.CrossRef Google Scholar PubMed

Koh, C. L., Viegas, O. A., Yuen, R., et al. Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period. Int. J. Gynaecol. Obstet., 1992; 38(1): 9–18.CrossRef Google Scholar PubMed

Wahlberg, T., Blomback, M., Hall, P., et al. Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Inf. Med., 1980; 19(4): 194–200.Google Scholar PubMed

Kouides, P. A.Menorrhagia from a haematologist's point of view. Part I: initial evaluation. Haemophilia, 2002; 8(3): 330–8.CrossRef Google Scholar PubMed

Siegel, J. E. and Kouides, P. A.Menorrhagia from a haematologist's point of view. Part II: management. Haemophilia 2002; 8(3): 339–47.CrossRef Google Scholar PubMed

Peterson, P., Hayes, T. E., Arkin, C. F., et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch. Surg., 1998; 133(2): 134–9.CrossRef Google Scholar PubMed

Favaloro, E. J.Utility of the PFA-100™ for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia, 2001; 7(2): 170–9.CrossRef Google Scholar

Wuillemin, W., Gasser, K., Zeerleder, S., et al. Evaluation of a Platelet Function Analyser (PFA-100™) in patients with a bleeding tendency. Swiss Med. Wkly., 2002(132): 443–8.Google Scholar

Roa, A. Disorders of platelet function. In Kitchens, C. S. A. B., and Kessler, C. M., eds. Consultative Hemostasis and Thrombosis. 1st edn. Philadelphia: W. B. Saunders; 2002. pp. 133–48.Google Scholar

Wilner, K. D., Rushing, M., Walden, C., et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J. Clin. Pharmacol., 2002; 42(9): 1027–30.CrossRef Google Scholar

Silverman, D. G., Halaszynski, T., Sinatra, R., et al. Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. Can. J. Anaesth., 2003; 50(10): 1004–8.CrossRef Google Scholar

Homoncik, M., Malec, M., Marsik, C., et al. Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin. Exp. Rheumatol., 2003; 21(2): 229–31.Google Scholar PubMed

Coukell, A. J. and Markham, A.Clopidogrel. Drugs, 1997; 54(5): 745–50; discussion p. 751.CrossRef Google Scholar PubMed

Pritchard, J. A., Weisman, R. Jr., Ratnoff, O. D., et al. Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. N. Engl. J. Med., 1954; 250(3): 89–98.CrossRef Google Scholar PubMed

Pitkin, R. M. and Witte, D. L.Platelet and leukocyte counts in pregnancy. JAMA, 1979; 242(24): 2696–8.CrossRef Google Scholar PubMed

Dilley, A., Drews, C., Miller, C., et al. Von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet. Gynecol., 2001; 97(4): 630–6.Google Scholar PubMed

Rodeghiero, F., Castaman, G. and Dini, E.Epidemiological investigation of the prevalence of von Willebrand's disease. Blood, 1987; 69(2): 454–9.Google Scholar PubMed

Edlund, M., Blomback, M., Schoultz, B., et al. On the value of menorrhagia as a predictor for coagulation disorders. Am. J. Hematol., 1996; 53(4): 234–8.3.0.CO;2-Z>CrossRef Google Scholar PubMed

Ruggeri, Z. M.Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract. Res. Clin. Haematol., 2001; 14(2): 257–79.CrossRef Google Scholar PubMed

Siediecki, C.Shear-dependant changes in the three-dimensional structure of human von Willebrand factor. Blood, 1996; 88: 2939–50.Google Scholar

Ruggeri, Z. M., Dent, J. A. and Saldivar, E.Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood, 1999; 94(1): 172–8.Google Scholar PubMed

Fujimoto, T. and Hawiger, J.Adenosine diphosphate induces binding of von Willebrand factor to human platelets. Nature, 1982; 297(5862): 154–6.CrossRef Google Scholar PubMed

Ni, H., Denis, C. V., Subbarao, S., et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J. Clin. Invest., 2000; 106(3): 385–92.CrossRef Google Scholar PubMed

Goto, S., Ikeda, Y., Saldivar, E., et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J. Clin. Invest., 1998; 101(2): 479–86.CrossRef Google Scholar PubMed

Seremetis S. and Afshani, V. Management of bleeding disorders in pregnancy. In Kitchens, C. S. A. B., and Kessler, C. M., eds. Consultative Hemostasis and Thrombosis. 1st edn. Philadelphia: W. B. Saunders; 2002. pp. 437–48.Google Scholar

Hennessy, B. J., White, B., Byrne, M., et al. Acquired von Willebrand's disease. Ir. J. Med. Sci., 1998; 167(2): 81–5.CrossRef Google Scholar PubMed

Nitu-Whalley, I. C. and Lee, C. A.Acquired von Willebrand syndrome – report of 10 cases and review of the literature. Haemophilia, 1999; 5(5): 318–26.CrossRef Google Scholar PubMed

Attivissimo, L. A., Lichtman, S. M. and Klein, I.Acquired von Willebrand's syndrome causing a hemorrhagic diathesis in a patient with hypothyroidism. Thyroid, 1995; 5(5): 399–401.CrossRef Google Scholar

Lak, M., Peyvandi, F. and Mannucci, P. M.Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br. J. Haematol., 2000; 111(4): 1236–9.CrossRef Google Scholar PubMed

Kroll, M.Manual of Coagulation Disorders. 1st edn. Malden, MA: Blackwell Science; 2001.Google Scholar

Castaman, G., Eikenboom, J. C., Contri, A., et al. Pregnancy in women with type 1 von Willebrand disease caused by heterozygosity for von Willebrand factor mutation C1130F. Thromb. Haemost., 2000; 84(2): 351–2.Google Scholar PubMed

Kouides, P. A.Obstetric and gynaecological aspects of von Willebrand disease. Best Pract. Res. Clin. Haematol., 2001; 14(2): 381–99.CrossRef Google Scholar PubMed

Sorosky, J., Klatsky, A., Nobert, G. F.Von Willebrand's disease complicating second-trimester abortion. Obstet. Gynecol., 1980; 55(2): 253–4.Google Scholar PubMed

Meyer, D., Fressinaud, E., Hilbert, L., et al. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best. Pract. Res. Clin. Haematol., 2001; 14(2): 349–64.CrossRef Google Scholar PubMed

Ginsburg, D. and Sadler, J. E.Von Willebrand disease: a database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost., 1993; 69(2): 177–84.Google Scholar

Ruggeri, Z. M. and Zimmerman, T. S.Classification of variant von Willebrand's disease subtypes by analysis of functional characteristics and multimeric composition of factor VIII/von Willebrand factor. Ann. NY. Acad. Sci., 1981; 370: 205–9.CrossRef Google Scholar PubMed

Weiss, H. J., Ball, A. P. and Mannucci, P. M.Incidence of severe von Willebrand's disease. N. Engl. J. Med., 1982; 307(2): 127.Google Scholar PubMed

Mannucci, P. M., Bloom, A. L., Larrieu, M. J., et al. Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel. Br. J. Haematol., 1984; 57(1): 163–9.CrossRef Google Scholar PubMed

Kadir, R. A., Economides, D. L., Sabin, C. A., et al. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb. Haemost., 1999; 82(5): 1456–61.CrossRef Google Scholar PubMed

Miller, C., Dilley, A. B., Drews, C., et al. Changes in von Willebrand factor and Factor VIII during the menstrual cycle. Thromb. Haemost., 2002; 87(6): 1082–3.Google Scholar PubMed

Mandalaki, T., Louizou, C., Dimitriadou, C., et al. Variations in factor VIII during the menstrual cycle in normal women. N. Engl. J. Med., 1980; 302(19): 1093–4.Google Scholar PubMed

Blomback, M., Eneroth, P., Andersson, O., et al. On laboratory problems in diagnosing mild von Willebrand's disease. Am. J. Hematol., 1992; 40(2): 117–20.CrossRef Google Scholar PubMed

Budde, U., Drewke, E., Mainusch, K., et al. Laboratory diagnosis of congenital von Willebrand disease. Semin. Thromb. Hemost., 2002; 28(2): 173–90.CrossRef Google Scholar PubMed

Enayat, M. S. and Hill, F. G.Analysis of the complexity of the multimeric structure of factor VIII related antigen/von Willebrand protein using a modified electrophoretic technique. J. Clin. Pathol., 1983; 36(8): 915–9.CrossRef Google Scholar PubMed

Walker, I. D., Walker, J. J., Colvin, B. T., et al. Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force. J. Clin. Pathol., 1994; 47(2): 100–8.CrossRef Google Scholar PubMed

Eikenboom, J. C.Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract. Res. Clin. Haematol., 2001; 14(2): 365–79.CrossRef Google Scholar PubMed

Batlle, J., Noya, M. S., Giangrande, P., et al. Advances in the therapy of von Willebrand disease. Haemophilia, 2002; 8(3): 301–7.CrossRef Google Scholar PubMed

Mannucci, P. M.How I treat patients with von Willebrand disease. Blood, 2001; 97(7): 1915–19.CrossRef Google Scholar

Chediak, J. R., Alban, G. M. and Maxey, B.Von Willebrand's disease and pregnancy: management during delivery and outcome of offspring. Am. J. Obstet. Gynecol., 1986; 155(3): 618–24.CrossRef Google Scholar PubMed

Mannucci, P. M.Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood, 1997; 90(7): 2515–21.Google Scholar PubMed

Mannucci, P. M.Hemostatic drugs. N. Engl. J. Med., 1998; 339(4): 245–53.CrossRef Google Scholar PubMed

Charles, K., Preston, F. and Makris, M.Successful use of desmopression (DDAVP) in pregnant women with inherited storage pool disease. Haemophilia, 2000; 6: 241.Google Scholar

Burrow, G., Wassenaar, W. and Robertson, G.DDAVP treatment of diabetes insipidus during pregnancy and the post-partum period. Acta Endocrinol., 1981; 97: 23–5.Google Scholar PubMed

Rochelson, B., Caruso, R., Davenport, D., et al. The use of prophylactic desmopressin (DDAVP) in labor to prevent hemorrhage in a patient with Ehlers-Danlos syndrome. NY State J. Med., 1991; 91(6): 268–9.Google Scholar

Weinbaum, P. J., Cassidy, S. B., Campbell, W. A., et al. Pregnancy management and successful outcome of Ehlers-Danlos syndrome type IV. Am. J. Perinatol., 1987; 4(2): 134–7.CrossRef Google Scholar PubMed

Ray, J. G.DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet. Gynecol. Surv., 1998; 53(7): 450–5.CrossRef Google Scholar PubMed

Mannucci, P. M., Lombardi, R., Bader, R., et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood, 1985; 66(4): 796–802.Google Scholar PubMed

Sadler, J. E., Mannucci, P. M., Berntorp, E., et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb. Haemost., 2000; 84(2): 160–74.CrossRef Google Scholar PubMed

Mazurier, C., Gaucher, C., Jorieux, S., et al. Biological effect of desmopressin in eight patients with type 2N (‘Normandy’) von Willebrand disease. Collaborative Group. Br. J. Haematol., 1994; 88(4): 849–54.CrossRef Google Scholar

Holmberg, L., Nilsson, I. M., Borge, L., et al. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type II B von Willebrand's disease. N. Engl. J. Med., 1983; 309(14): 816–21.CrossRef Google Scholar

Fausett, B. and Silver, R. M.Congenital disorders of platelet function. Clin. Obstet. Gynecol. 1999; 42(2): 390–405.CrossRef Google Scholar PubMed

Sage, D. J.Epidurals, spinals and bleeding disorders in pregnancy: a review. Anaesth. Intensive Care, 1990; 18(3): 319–26.Google Scholar PubMed

Phillips, M. D. and Santhouse, A.von Willebrand disease: recent advances in pathophysiology and treatment. Am. J. Med. Sci., 1998; 316(2): 77–86.Google Scholar PubMed

Pales, J. L., Lopez, A., Asensio, A., et al. Inhibitory effect of peak 2–4 of uremic middle molecules on platelet aggregation. Eur. J. Haematol., 1987; 39(3): 197–202.CrossRef Google Scholar PubMed

Bazilinski, N., Shaykh, M., Dunea, G., et al. Inhibition of platelet function by uremic middle molecules. Nephron, 1985; 40(4): 423–8.CrossRef Google Scholar PubMed

Moal, V., Brunet, P., Dou, L., et al. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol. Dial. Transplant, 2003; 18(9): 1834–41.CrossRef Google Scholar PubMed

Kunicki T. J. Platelet immunology. In Colman, R. W., Hirsh, J., Marder, V. J., et al., eds. Hemostasis and Thrombosis: Basic Principles & Clinical Practice. 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2001, pp. 461–77.Google Scholar

Ramasamy, I.Inherited bleeding disorders: disorders of platelet adhesion and aggregation. Crit. Rev. Oncol. Hematol., 2004; 49(1): 1–35.CrossRef Google Scholar PubMed

Khalil, A., Seoud, M., Tannous, R., et al. Bernard-Soulier syndrome in pregnancy: case report and review of the literature. Clin. Lab. Haematol., 1998; 20(2): 125–8.CrossRef Google Scholar PubMed

Laurian, Y.Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?Pathophysiol. Haemost. Thromb., 2002; 32(Suppl. 1): 37–40.CrossRef Google Scholar

Caglar, K., Cetinkaya, A., Aytac, S., et al. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr. Hematol. Oncol., 2003; 20(6): 435–8.CrossRef Google Scholar PubMed

Poon, M. C., d'Oiron, R., Hann, I., et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin. Hematol., 2001; 38(4 Suppl. 12): 21–5.CrossRef Google Scholar PubMed

Almeida, A. M., Khair, K., Hann, I.The use of recombinant factor VIIa in children with inherited platelet function disorders. Br. J. Haematol., 2003; 121(3): 477–81.CrossRef Google Scholar PubMed

Lusher, J. M. and McMillan, C. W.Severe factor VIII and factor IX deficiency in females. Am. J. Med., 1978; 65(4): 637–48.CrossRef Google Scholar PubMed

Seligsohn, U.High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood, 1978; 51(6): 1223–8.Google Scholar PubMed

Bauduer, F., Dupreuilh, F., Ducout, L., et al. Factor XI deficiency in the French Basque Country. Haemophilia, 1999; 5(3): 187–90.CrossRef Google Scholar PubMed

Kadir, R. A., Economides, D. L. and Lee, C. A.Factor XI deficiency in women. Am. J. Hematol., 1999; 60(1): 48–54.3.0.CO;2-Q>CrossRef Google Scholar PubMed

Bolton-Maggs, P. H., Wan-Yin, Young B., McCraw, A. H., et al. Inheritance and bleeding in factor XI deficiency. Br. J. Haematol., 1988; 69(4): 521–8.CrossRef Google Scholar PubMed

Bolton-Maggs, P. H., Colvin, B. T., Satchi, B. T., et al. Thrombogenic potential of factor XI concentrate. Lancet, 1994; 344(8924): 748–9.CrossRef Google Scholar PubMed

Roberts, H. and Escobar, M. Less common congenital disorders of hemostasis. In Kitchens, C. S. A. B., and Kessler, C. M., eds. Consultative Hemostasis and Thrombosis. Philadelphia: W. B. Saunders; 2002, pp. 57–73.Google Scholar

Green, D. and Lechner, K.A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb. Haemost., 1981; 45(3): 200–3.Google Scholar PubMed

Hauser, I., Schneider, B. and Lechner, K.Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb. Haemost., 1995; 73(1): 1–5.Google Scholar PubMed

Delgado, J., Jimenez-Yuste, V., Hernandez-Navarro, F., Villar, A.et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br. J. Haematol., 2003; 121(1): 21–35.CrossRef Google Scholar PubMed

Rubinger, M., Rivard, G. E., Teitel, J., et al. Suggestions for the management of factor VIII inhibitors. Haemophilia, 2000; 6(Suppl. 1): 52–9.Google Scholar PubMed

Ewenstein B., Putnam K. and Bohn R. Nonhemophilic inhibitors of coagulation. In Kitchens, C. S., Alving, B. M. and Kessler, C. M., eds. Consultative Hemostasis and Thrombosis. Philadelphia: W. B. Saunders; 2002, pp. 75–90.Google Scholar

Rubinger, M., Houston, D. S., Schwetz, N., et al. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors. Am. J. Hematol., 1997; 56(2): 112–8.3.0.CO;2-1>CrossRef Google Scholar PubMed

Shulman, N. R. and Hirschman, R. J.Acquired hemophilia. Trans. Assoc. Am. Physicians, 1969; 82: 388–97.Google Scholar PubMed

Green, D.Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood, 1971; 37(4): 381–7.Google Scholar PubMed

Spero, J. A., Lewis, J. H. and Hasiba, U.Corticosteroid therapy for acquired F VIII: C inhibitors. Br. J. Haematol., 1981; 48(4): 635–42.CrossRef Google Scholar PubMed

Schwartz, R. S., Gabriel, D. A., Aledort, L. M., et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood, 1995; 86(2): 797–804.Google Scholar PubMed

Sultan, Y., Kazatchkine, M. D., Nydegger, U., et al. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII: C inhibitors. Am. J. Med., 1991; 91(5A): 35–9(S).CrossRef Google Scholar PubMed

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this chapter is currently unknown and may be updated in the future.